|
業務類別
|
Biotechnology |
|
業務概覽
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM,diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
| 公司地址
| 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 850-5070 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.mazetx.com |
| 員工數量
| 125 |
| Mr. Misbah Tahir |
Chief Financial Officer |
美元 164.77K |
28/04/2026 |
| Ms. Courtney J. Phillips |
General Counsel and Corporate Secretary |
-- |
28/04/2026 |
| Dr. Harold S. Bernstein |
President, Research and Development and Chief Medical Officer |
美元 548.33K |
28/04/2026 |
| Mr. Atul Dandekar |
Chief Strategy and Business Officer |
-- |
28/04/2026 |
| Dr. Jason V. Coloma, PhD |
Chief Executive Officer and Director |
美元 629.17K |
28/04/2026 |
| Ms. Amy Bachrodt |
Senior Vice Preisdent, Finance and Principal Accounting Officer |
-- |
25/03/2026 |
|
|
| Dr. Richard H. Scheller, PhD |
Independent Director |
28/04/2026 |
| Dr. Neil Kumar, PhD |
Director |
25/03/2026 |
| Dr. Charles J. Homcy,M.D. |
Director |
28/04/2026 |
| Mr. Herve Hoppenot |
Chairman of the Board |
28/04/2026 |
| Dr. Catherine Angell Sohn, Pharm.D. |
Independent Director |
28/04/2026 |
| Dr. Jason V. Coloma, PhD |
Chief Executive Officer and Director |
28/04/2026 |
| Dr. Nancy C. Andrews, M.D.,PhD |
Independent Director |
28/04/2026 |
| Mr. Neil Exter, M.B.A. |
Independent Director |
25/03/2026 |
| Mr. Daniel K. Spiegelman |
Independent Director |
28/04/2026 |
| Dr. Jonathan E. Lim,M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
